1. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des. 2008;14 (30):3219-30.
2. White JA, Fine NM. Recent Advances in Cardiovascular Imaging Relevant to the Management of Patients with Suspected Cardiac Amyloidosis. Curr Cardiol Rep. 2016 Aug; 18 (8):77 doi:10.1007/s11886-016-0752-7.
3. Мясников Р. П., Андреенко Е. Ю., Кушунина Д. В., и др. Амилоидоз сердца: современные аспекты диагностики и лечения (клиническое наблюдение). Клин. и эксперимент. хир. Журн. им. акад. Б.В. Петровского. 2014;4:72-82.
4. Brunjes DL, Dunlop M, Wu C, et al. Analysis of Skeletal Muscle Torque Capacity and Circulating Ceramides in Patients with Advanced Heart Failure. J Card Fail. 2016 May; 22 (5):347-55. doi:10.1016/j.cardfail.2016.02.002.
5. Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency approved drug. J Molec Biol. 2012 Aug 10;421 (2-3):185-203. doi:101016/j.jmb.2011.12.060.
6. Miller WL, Wright RS, McGregor CG, et al. Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. Am. J. Cardiol. 2001 Oct 1;88 (7):813-5.
7. Nakagawa M, Sekijima Y, Yazaki M, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016;23 (1):58-63. doi:10.3109/13506129.2015.1135792.
8. Treibel T, Fontana M, Maestrini V, et al. Automatic Measurement of the Myocardial Interstitium: Synthetic Extracellular Volume Quantification Whithout Hematocrit Sampling. JACC Cardiovasc Imaging 2016 Jan; 9 (1):54-63. doi:10.1016/j.jcmg.2015.11.008.
9. Bhogal S, Ladia V, Sitwala P, et al. Cardiac Amyloidosis: An Updated Review with Emphasis on Diagnosis and Future Directions. Curr Probl Cardiol. 2018 Jan;43 (1):10-34. doi:10.1016/j.cpcardiol.2017.04.003.
10. Donnelly JP., Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017 Dec;84 (12 Suppl 3):12-26. doi:10.3949/ccjm.84.s3.02.
11. Minutoli F, Di Bella G, Mazzeo A, et al. Comparison between (99m) Tc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy. Am J Roentgenology. 2013 Mar; 200 (3): W256-65. doi:10.2214/AJR.12.8737.
12. Bokhari S, Castano A, Pozniakoff T, et al. (99m) Tc-Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circulation Cardiovascular Imaging. 2013 Mar 1;6 (2):195-201. doi:10.1161/CIRCIMAGING.112.000132.
13. Siddiqi OK, Ruberg FL. Cardiac Amyloidosis: An Update on Pathophysiology, Diagnosis, and Treatment. Trends in Cardiovasc Med. 2018 Jan;28 (1):10-21. doi:10.1016/j.tcm.2017.07.004.
14. Sousa M, Monohan G, Rajagopalan N, et al. Heart Transplantation in Cardiac Amyloidosis. Heart Fail Rev. 2017 May;22 (3):317-27 doi:10.1007/s10741-017-9601-z.
15. Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015 Mar;20 (2):117-24. doi:10.1007/s10741-015-9480-0.